PMID- 22870740
OWN - NLM
STAT- MEDLINE
DCOM- 20120920
LR  - 20191112
IS  - 0001-5385 (Print)
IS  - 0001-5385 (Linking)
VI  - 67
IP  - 3
DP  - 2012 Jun
TI  - The predictive value of QRS duration in response to levosimendan therapy in 
      patients with decompensated heart failure.
PG  - 317-23
AB  - PURPOSE: We aimed to investigate the role of QRS duration on the surface 
      electrocardiogram (ECG) in predicting response to levosimendan therapy in 
      patients with acute systolic heart failure. METHODS: Patients with an ejection 
      fraction (EF) lower than 35% who required intravenous inotropic support despite 
      optimal heart failure therapy were included in this study. Patients were divided 
      into two groups according to QRS durations on ECG. Group 1 (n=16) included 
      patients with a QRS duration equal to or shorter than 120 ms and group 2 (n=14) 
      included patients with a QRS duration longer than 120 ms. New York Heart 
      Association (NYHA) functional class, plasma BNP levels and echocardiographic 
      measurements were compared within and between groups before and after the 
      infusion. RESULTS: In both groups statistically significant improvement was 
      observed in NYHA class, plasma BNP levels and left ventricular end-systolic 
      diameter after the levosimendan infusion compared to baseline (P < 0.025). In 
      addition, in group 1 patients, left atrial diameter, left atrial volume, left 
      ventricular end-diastolic diameter, left ventricular end-diastolic volume, left 
      ventricular end-systolic volume (LVESV), left ventricular EF, mitral E velocity, 
      mitral annular Aa and Sa parameters improved after the infusion compared to the 
      baseline values (P < 0.025). Comparison of both groups revealed improvement of 
      NYHA class, an increase of left ventricular EF and a signficant decrease of LVESV 
      after levosimendan in group 1 (P < 0.05). CONCLUSION: QRS duration on ECG may be 
      used as a practical bedside indicator in estimating short-term response to 
      levosimendan therapy.
FAU - Cetin, Mustafa
AU  - Cetin M
AD  - Ataturk Chest Disease and Chest Surgery Education and Research Hospital, 
      Department of Cardiology, Ankara, Turkey. mdmustafacetin@yahoo.com
FAU - Ucar, Ozgul
AU  - Ucar O
FAU - Cicekcioglu, Hulya
AU  - Cicekcioglu H
FAU - Guven Cetin, Zehra
AU  - Guven Cetin Z
FAU - Sahin, Muslum
AU  - Sahin M
FAU - Vasfi Ulusoy, Feridun
AU  - Vasfi Ulusoy F
FAU - Aydogdu, Sinan
AU  - Aydogdu S
LA  - eng
PT  - Journal Article
PL  - England
TA  - Acta Cardiol
JT  - Acta cardiologica
JID - 0370570
RN  - 0 (Biomarkers)
RN  - 0 (Cardiotonic Agents)
RN  - 0 (Hydrazones)
RN  - 0 (Pyridazines)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 349552KRHK (Simendan)
SB  - IM
MH  - Biomarkers/blood
MH  - Cardiotonic Agents/administration & dosage/*therapeutic use
MH  - Chi-Square Distribution
MH  - Echocardiography
MH  - *Electrocardiography
MH  - Female
MH  - Heart Failure/blood/diagnostic imaging/*drug therapy/physiopathology
MH  - Humans
MH  - Hydrazones/administration & dosage/*therapeutic use
MH  - Infusions, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/blood
MH  - Predictive Value of Tests
MH  - Pyridazines/administration & dosage/*therapeutic use
MH  - Simendan
MH  - Statistics, Nonparametric
MH  - Systole/physiology
MH  - Treatment Outcome
EDAT- 2012/08/09 06:00
MHDA- 2012/09/21 06:00
CRDT- 2012/08/09 06:00
PHST- 2012/08/09 06:00 [entrez]
PHST- 2012/08/09 06:00 [pubmed]
PHST- 2012/09/21 06:00 [medline]
AID - 10.1080/ac.67.3.2160721 [doi]
PST - ppublish
SO  - Acta Cardiol. 2012 Jun;67(3):317-23. doi: 10.1080/ac.67.3.2160721.